While the National Council already had its last session before the summer holidays, the ÖVP’s corruption inquiry commission will move to a new round next week. National Council President Wolfgang Sobotka, former Economy Minister Margarete Schramböck (both ÖVP) and officials of the Federal Anti-Corruption Office (BAK) testified on two days of the investigation.
Sobotka will start on Wednesday. The director of the BAK and a now retired BAK official are also on the program on this day. The Federal Anti-Corruption Agency was already conducting investigations before the Ibiza video was released in 2019. Former Minister of Economic Affairs Margarete Schramböck will follow on Thursday. Originally, the Director of the Federal Police and former Refugee Coordinator Michael Takacs, as well as the former Private Secretary to former Deputy Minister of Agriculture Elisabeth Köstinger, Gernot Maier, were planned. Both will be prevented on Thursday, however.
Questions about studies of Karmasin
The focus of the surveys should be on conducting surveys, surveys and advertisements. An example is the ‘role model process’ under opinion researcher and former family minister Sophie Karmasin (ÖVP) between 2019 and 2020. This was carried out on behalf of the Ministry of Economic Affairs and is said to have cost 125,920 euros in taxpayers’ money. The opposition criticizes that the process has barely yielded any results. Both she and the Green government partner suspect that the questions would have been in the interest of the ÖVP or former Chancellor Sebastian Kurz. The Public Prosecutor’s Office for Business and Corruption is investigating a complaint in this case.
After the next two days of the investigation, the ÖVP’s Corruption Investigation Commission takes a break.
Source: Krone
I’m an experienced news author and editor based in New York City. I specialize in covering healthcare news stories for Today Times Live, helping to keep readers informed on the latest developments related to the industry. I have a deep understanding of medical topics, including emerging treatments and drugs, the changing laws that regulate healthcare providers, and other matters that affect public health.
